Australia Poisons Standard (SUSMP) s64-D: For Schedule 4 and 8 poisons in Appendix D, supply or prescribe only by the specified practitioner class, exclude pregnancy and give pregnancy advice where required, require authority to possess listed substances, store listed injectables locked, and limit MDMA and psilocybine to authorised psychiatrists or approved trials

What does s64-D require?

Appendix D adds controls applied through section 64. For human use, some poisons may be supplied only by, or on the prescription of, an authorised medical practitioner (for example cannabis, clozapine, sodium oxybate, follitropins, teriparatide), a medical practitioner covered by an approval or authority under the Act's section 19 (dronabinol), a specialist physician or dermatologist (acitretin, bexarotene, etretinate, oral isotretinoin, thalidomide), a specialist physician (lenalidomide, pomalidomide, riociguat, oral tretinoin; ambrisentan, bosentan, enzalutamide, macitentan, sitaxentan) or a dermatologist (alefacept); for women of child-bearing age the prescriber must first exclude pregnancy and advise avoiding pregnancy for the specified period (36 months, 3 months or 1 month after treatment depending on the medicine). Listed substances (such as anabolic and androgenic steroids, benzodiazepines, growth hormone secretagogues and peptides, erythropoietins, ephedrine, nicotine, phentermine, SARMs, somatropin and tianeptine) must not be possessed without authority. Injectable pentobarbital must be kept in a locked container. MDMA for post-traumatic stress disorder and psilocybine for treatment-resistant depression may be supplied only on the prescription or authorisation of a registered specialist psychiatrist holding a section 19(5) authority, or in an approved or notified clinical trial.